EliTech, R-Biopharm team up
August 2018—EliTechGroup and R-Biopharm announced an agreement in which the two companies will develop, produce, and market real-time PCR reagents.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Agilent companion Dx gets expanded approval
August 2018—Agilent Technologies announced that the FDA has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use. PD-L1 IHC 22C3 pharmDx is a laboratory test doctors can use to identify the protein programmed cell death ligand 1 in tumor tissue obtained from patients with lung and gastric cancer.
Meridian monoclonal antibodies
August 2018—Meridian Life Science released Japanese encephalitis virus pairs suitable for use in ELISAs and immunofluorescence assays. The product is specific for the nonstructural protein 1 (NS1) and exhibits no cross-reactivity with other flaviviruses, including tick-borne encephalitis, yellow fever, West Nile, dengue, Zika, and chikungunya.
MilliporeSigma, HistoCyte Labs distribution agreement
August 2018—MilliporeSigma has entered into an agreement with HistoCyte Laboratories (Tyne, U.K.) to be the exclusive multinational distributor of HistoCyte’s cell line reference products for immunohistochemistry and in situ hybridization.
Ortho Vitros XT 7600 gets CE mark
August 2018—Ortho Clinical Diagnostics received the CE mark for the Ortho Vitros XT 7600 integrated chemistry system. The digital chemistry is based on three technologies: dry slide, microslide, and digital imaging. Dry slide technology does not require water to run, which eliminates the risk of poor water quality affecting test results.
Long-term implantable CGM gets FDA approval
August 2018—The FDA has approved Senseonics Holdings’ Eversense Continuous Glucose Monitoring System for adults age 18 and older with diabetes. The system features an implantable glucose sensor and provides long-term continuous monitoring for up to three months.
FDA clears ASI Evolution
July 2018—Arlington Scientific announced it has received FDA 510(k) clearance for its ASI Evolution, a fully automated nontreponemal syphilis system for diagnostic testing and blood donor screening.
CARB-X awards Specific Diagnostics $1.7 million
July 2018—CARB-X has awarded Specific Diagnostics up to $1.7 million to support the development of the company’s antibiotic susceptibility testing system. Up to $1.7 million more could be awarded based on achievement of project milestones. Specific’s AST instrument determines phenotypic antibiotic susceptibility within hours of blood infection.
Cancer Genetics modifies TOO test
July 2018—Cancer Genetics announced it has received special 510(k) clearance from the FDA for its Tissue of Origin test following modifications made to test reagents and software.
Liquichek AMH Control
July 2018—Bio-Rad Laboratories has launched its Liquichek AMH Control for reproductive health testing.